Nanjing Ruijie Pharma Co., Ltd.

Primary objective: To evaluate the bioequivalence of the two preparations in the fasting state in humans by using the leprocaine cream (specification: 1g: lidocaine 25mg, prilocaine 25mg, produced by Hangzhou Lingye Pharmaceutical Technology Co., Ltd.) provided by Nanjing Ruijie Pharmaceutical Technology Co., Ltd. as the test preparation and the leprocaine cream (trade name: Emla, specification: 1g: lidocaine 25mg, prilocaine 25mg) certified by Aspen Pharmacare Australia Pty Ltd as the reference preparation through a single-center, randomized, open, single-dose, two-sequence, two-period, double-crossover clinical study. Secondary objective: To evaluate the safety of the test preparation T and reference preparation R of leprocaine cream in healthy subjects.

The main purpose of the study is to use the metformin hydrochloride sustained-release tablets (trade name: GLUCOPHAGE XR, 0.5 g) of the original research company Bristol-Myers Squibb Company as the reference preparation and the metformin hydrochloride sustained-release tablets (0.5 g) of Nanjing Ruijie Pharmaceutical Technology Co., Ltd. as the test preparation to evaluate the human bioequivalence of the two preparations through a single-center, randomized, open, single-dose, two-cycle, double-crossover clinical study. Secondary purpose of the study: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.